For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

While House, Senate thwarted 40% cut to agency’s budget, about half of the largest recipients of agency grants saw cuts year-over-year.

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

The Center supports clients across the development and manufacturing of biologics, RNA therapeutics, vaccines, and cell and gene therapies.

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.

While there are several bacteria and viruses causing pneumonia, the research team looked specifically at Streptococcus pneumoniae.

In the 1980s, the human immunodeficiency virus (HIV) was a global scourge, decimating communities. When it was identified in the blood products supply chain, people were terrified.

With the advent of AI-powered protein design tools, protein-based therapeutics may no longer be constrained by the limits imposed by natural selection.

Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.